$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2023 Q4 Form 10-Q Financial Statement

#000147793223008458 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $3.000K $6.000K $18.60K
YoY Change -83.87% -89.09% -72.55%
Cost Of Revenue $1.200K $2.400K $5.700K
YoY Change -78.95% -85.0% -85.55%
Gross Profit $1.800K $3.600K $12.90K
YoY Change -86.05% -90.77% -54.42%
Gross Profit Margin 60.0% 60.0% 69.35%
Selling, General & Admin $1.399M $531.0K $899.6K
YoY Change 55.48% -34.07% -37.0%
% of Gross Profit 77706.11% 14751.17% 6973.64%
Research & Development $349.4K $992.7K $5.000M
YoY Change -93.01% 329.86% 9900.0%
% of Gross Profit 19411.67% 27575.61% 38759.69%
Depreciation & Amortization $24.58K $20.00K $23.02K
YoY Change 6.78% -13.12% 0.0%
% of Gross Profit 1365.56% 555.56% 178.45%
Operating Expenses $1.774M $1.547M $5.000M
YoY Change -64.53% 46.0% 233.1%
Operating Profit -$1.772M -$1.543M -$4.987M
YoY Change -64.47% 51.23% 238.63%
Interest Expense $93.27K $90.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $89.23K $62.25K
YoY Change 134.31%
Pretax Income -$1.679M -$1.454M -$6.216M
YoY Change -72.99% 48.01% 60.39%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.679M -$1.454M -$6.216M
YoY Change -72.99% 48.01% 60.39%
Net Earnings / Revenue -55952.33% -24232.53% -33417.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.22 -$1.02 -$0.44
COMMON SHARES
Basic Shares Outstanding 1.382M shares 1.431M shares 14.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.987M $4.510M $8.321M
YoY Change 20.03% -73.42% -22.41%
Cash & Equivalents $3.467M $4.507M $8.321M
Short-Term Investments $6.520M
Other Short-Term Assets $277.3K $7.530M $10.42M
YoY Change -97.34% 49.96%
Inventory $6.594K $7.794K $10.19K
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $10.27M $12.04M $18.75M
YoY Change -45.21% -45.27% 74.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.280K $0.00 $3.280K
YoY Change 0.0% -100.0% -0.03%
Total Long-Term Assets $444.3K $469.8K $438.9K
YoY Change 1.23% 1.71% -17.34%
TOTAL ASSETS
Total Short-Term Assets $10.27M $12.04M $18.75M
Total Long-Term Assets $444.3K $469.8K $438.9K
Total Assets $10.72M $12.51M $19.19M
YoY Change -44.15% -44.31% 70.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $317.3K $367.0K $3.268M
YoY Change -90.29% 11.96% 328.89%
Accrued Expenses $39.92K $39.92K $39.92K
YoY Change 0.0% -27.31% 63.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $371.4K $421.2K $3.322M
YoY Change -88.82% 6.1% 216.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $371.4K $421.2K $3.322M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $371.4K $421.2K $3.322M
YoY Change -88.82% 6.1% 216.22%
SHAREHOLDERS EQUITY
Retained Earnings -$59.10M -$57.42M -$53.81M
YoY Change 9.82% 20.64% 23.23%
Common Stock $1.431K $1.431K $14.08K
YoY Change -89.83% -89.83% 122.07%
Preferred Stock
YoY Change
Treasury Stock (at cost) $271.0K $191.8K $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity $10.34M $12.09M $15.86M
YoY Change
Total Liabilities & Shareholders Equity $10.72M $12.51M $19.19M
YoY Change -44.15% -44.31% 70.27%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$1.679M -$1.454M -$6.216M
YoY Change -72.99% 48.01% 60.39%
Depreciation, Depletion And Amortization $24.58K $20.00K $23.02K
YoY Change 6.78% -13.12% 0.0%
Cash From Operating Activities -$1.898M -$1.300M -$3.591M
YoY Change -47.15% 48.86% 209.24%
INVESTING ACTIVITIES
Capital Expenditures $100.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.225M $1.820M -$5.057M
YoY Change -124.23% -136.25%
Cash From Investing Activities $1.125M $1.820M -$5.057M
YoY Change -122.25% -136.25% -2628.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -271.0K 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.898M -1.300M -3.591M
Cash From Investing Activities 1.125M 1.820M -5.057M
Cash From Financing Activities -271.0K 0.000 0.000
Net Change In Cash -1.044M 520.0K -8.649M
YoY Change -87.93% -108.82% -203.63%
FREE CASH FLOW
Cash From Operating Activities -$1.898M -$1.300M -$3.591M
Capital Expenditures $100.0K
Free Cash Flow -$1.998M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
12092380 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
12043726 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
3281 usd
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1431126 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1391126 shares
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1059422 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
61478 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
338120 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
435595 usd
CY2023Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
7467346 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
3281 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1431 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702587 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2400 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
3600 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
531042 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1546785 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
10194 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
18747450 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
466532 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
421159 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69675124 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8320519 usd
CY2022Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
10078617 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
7794 usd
CY2023Q3 us-gaap Assets
Assets
12513539 usd
CY2022Q4 us-gaap Assets
Assets
19186326 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
367045 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3267538 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39920 usd
CY2023Q3 celz Due To Related Party Current
DueToRelatedPartyCurrent
14194 usd
CY2022Q4 celz Due To Related Party Current
DueToRelatedPartyCurrent
14194 usd
CY2023Q3 us-gaap Revenues
Revenues
6000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
992722 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1543185 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
89233 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
89233 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1453952 usd
CY2023Q3 celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-1.02
CY2023Q3 celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1431426 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001187953
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
celz Amortization Expenses
AmortizationExpenses
18750 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53500
dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0622284
dei Entity Address Address Line1
EntityAddressAddressLine1
211 E Osborn Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Phoenix
dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85012
dei City Area Code
CityAreaCode
480
dei Local Phone Number
LocalPhoneNumber
399-2822
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CELZ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1382126 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4507108 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39920 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3321652 usd
CY2023Q3 us-gaap Liabilities
Liabilities
421159 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3321652 usd
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1407624 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1407624 shares
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
40000 shares
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
191780 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12513539 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19186326 usd
CY2022Q3 us-gaap Revenues
Revenues
55000 usd
us-gaap Revenues
Revenues
6000 usd
us-gaap Revenues
Revenues
70000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
16000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2400 usd
us-gaap Cost Of Revenue
CostOfRevenue
22791 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
39000 usd
us-gaap Gross Profit
GrossProfit
3600 usd
us-gaap Gross Profit
GrossProfit
47209 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
230940 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1621231 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
900635 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
805461 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2161599 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3043946 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69063 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69063 usd
us-gaap Operating Expenses
OperatingExpenses
3851893 usd
us-gaap Operating Expenses
OperatingExpenses
4013644 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1020422 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3848293 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3966435 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
38083 usd
us-gaap Interest Income Other
InterestIncomeOther
240293 usd
us-gaap Interest Income Other
InterestIncomeOther
38083 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38083 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
240293 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38083 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-982339 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3608000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3928352 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1453952 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-982339 usd
us-gaap Net Income Loss
NetIncomeLoss
-3608000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3928352 usd
CY2022Q3 celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-0.70
celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-2.55
celz Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-3.98
CY2022Q3 celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1406841 shares
celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1416319 shares
celz Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
987245 shares
us-gaap Net Income Loss
NetIncomeLoss
-3608000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3928352 usd
us-gaap Share Based Compensation
ShareBasedCompensation
27486 usd
us-gaap Share Based Compensation
ShareBasedCompensation
59584 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69063 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69063 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2485 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2400 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5028 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-276642 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2900493 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-434019 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
30535 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6132902 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4205732 usd
us-gaap Payments For Deposits On Real Estate Acquisitions
PaymentsForDepositsOnRealEstateAcquisitions
6437188 usd
us-gaap Payments For Deposits On Real Estate Acquisitions
PaymentsForDepositsOnRealEstateAcquisitions
5021307 usd
celz Proceeds From Redemptions Of Certificates Of Deposit
ProceedsFromRedemptionsOfCertificatesOfDeposit
9048459 usd
celz Proceeds From Redemptions Of Certificates Of Deposit
ProceedsFromRedemptionsOfCertificatesOfDeposit
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
191780 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2319491 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5021307 usd
celz Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
celz Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
15471775 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
457 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15472232 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3713411 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6245193 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8320519 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10723870 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4507108 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16969063 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
celz Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
0 usd
celz Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
250000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15864674 usd
celz Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
191780 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27486 usd
us-gaap Profit Loss
ProfitLoss
-3608000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
12092380 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13728950 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
191780 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9162 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1453952 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
12092380 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10217740 usd
celz Stock Issued During Period Value Common Stock And Accompanying Warrants Net Of Issuance Costs Shares
StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares
15471775 usd
celz Common Stock Issued For Related Party Patent Liabilities Amount
CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount
250000 usd
celz Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
457 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59584 usd
us-gaap Profit Loss
ProfitLoss
-3928352 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
22071204 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23044369 usd
CY2022Q3 celz Stock Issued During Period Shares Common Stock And Accompanying Warrants Net Of Issuance Costs
StockIssuedDuringPeriodSharesCommonStockAndAccompanyingWarrantsNetOfIssuanceCosts
0 usd
CY2022Q3 celz Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
12 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9162 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-982339 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
22071204 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates –</strong></em>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
40000 usd
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
55000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Concentration Risks</em></strong> – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of September 30, 2023, the Company’s balance exceeded the limit at two institutions.</p>
CY2023Q3 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2016Q1 celz Number Of Share Exchange
NumberOfShareExchange
43112 shares
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2017Q2 celz Payments Upon Completion Of Irb Clinical Trial
PaymentsUponCompletionOfIrbClinicalTrial
200000 usd
CY2023Q3 celz Company Paid
CompanyPaid
50000 usd
CY2020Q4 celz Company Paid
CompanyPaid
50000 usd
CY2020Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
300000 usd
CY2021Q3 celz Company Paid
CompanyPaid
40000 usd
CY2021Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
300000 usd
CY2021Q1 celz Company Paid
CompanyPaid
50000 usd
CY2021Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
300000 usd
CY2023Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
300000 usd
CY2017Q2 celz Payments In The Event Of Commercialization Of Technology
PaymentsInTheEventOfCommercializationOfTechnology
300000 usd
CY2022Q1 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
18018 shares
celz Amortization Expenses
AmortizationExpenses
18750 usd
CY2023Q3 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
181250 usd
CY2020Q4 us-gaap Payments For Fees
PaymentsForFees
25000 usd
CY2022Q4 celz Licensing Agreements
LicensingAgreements
760000 usd
CY2022Q4 celz Accumulated Amortization Of Licensing Agreements
AccumulatedAmortizationOfLicensingAgreements
-324405 usd
celz Accumulated Amortization Addition Of New Assets
AccumulatedAmortizationAdditionOfNewAssets
100000 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 usd
celz Accumulated Amortization
AccumulatedAmortization
-69063 usd
CY2023Q3 celz Licensing Agreements
LicensingAgreements
860000 usd
CY2023Q3 celz Accumulated Amortization Of Licensing Agreements
AccumulatedAmortizationOfLicensingAgreements
-393468 usd
CY2023Q3 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
100000 usd
CY2022Q4 celz Initial Payment Amount
InitialPaymentAmount
2000000 usd
CY2023Q1 celz Initial Payment Amount
InitialPaymentAmount
5000000 usd
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
299167 shares
CY2022Q2 celz Purchase Of Pre Funded Warrant And Related Common Warrant
PurchaseOfPreFundedWarrantAndRelatedCommonWarrant
1511112 shares
CY2022Q2 celz Combined Offering Price Of Pre Funded Warrant And Related Common Warrant
CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant
22.50
CY2022Q2 celz Description Of Amendment
DescriptionOfAmendment
pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
celz Common Warrants Exercise Price
CommonWarrantsExercisePrice
20.00
celz Pre Funded Warrants Exercise Price
PreFundedWarrantsExercisePrice
0.001
CY2023Q3 celz Repurchase Of Stock
RepurchaseOfStock
2000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0081 pure
us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.9295 pure
CY2023Q3 us-gaap Share Price
SharePrice
18.30
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000000 usd

Files In Submission

Name View Source Status
0001477932-23-008458-index-headers.html Edgar Link pending
0001477932-23-008458-index.html Edgar Link pending
0001477932-23-008458.txt Edgar Link pending
0001477932-23-008458-xbrl.zip Edgar Link pending
celz-20230930.xsd Edgar Link pending
celz_10q.htm Edgar Link pending
celz_10qimg3.jpg Edgar Link pending
celz_ex311.htm Edgar Link pending
celz_ex312.htm Edgar Link pending
celz_ex321.htm Edgar Link pending
celz_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
celz-20230930_cal.xml Edgar Link unprocessable
celz-20230930_lab.xml Edgar Link unprocessable
celz-20230930_def.xml Edgar Link unprocessable
celz-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
celz_10q_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending